The Stoller Biomarker Discovery Centre (SBDC) is part of The University of Manchester and is funded by the Medical Research Council, a philanthropic donation from the Stoller Charitable Trust, and developed in partnership with SCIEX. With 15 high-end mass spectrometers, the Centre is one of the biggest clinical proteomics facilities in the world and the largest in Europe.
At SBDC, our researchers help to industrialise the process of identifying biomarkers and aid in the translation of biomarkers into the clinical lab. We aim to find protein markers in the blood that could be used to stop patients being given treatments which won’t improve their condition. These markers will be developed to ensure doctors can prescribe the right treatment for the right patient as early as possible.
We also find new targets for drugs in specific diseases, such as chronic myeloid leukaemia and markers for the earlier detection of ovarian cancer – crucial in starting early treatment to save lives. Work to identify new biomarkers for diseases such as arthritis, cardiovascular, Alzheimer’s and psoriasis is also being advanced.
Please visit our stand if you would like to develop such a project, or visit our website www.manchester.ac.uk/sbdc for further information.